Financial Metrics Check: Trevi Therapeutics Inc (TRVI)’s Ratios for Trailing Twelve Months

Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Trevi Therapeutics Inc’s stock clocked out at $2.49, down -7.09% from its previous closing price of $2.68. In other words, the price has decreased by -$7.09 from its previous closing price. On the day, 0.67 million shares were traded. TRVI stock price reached its highest trading level at $2.73 during the session, while it also had its lowest trading level at $2.36.

Ratios:

To gain a deeper understanding of TRVI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.38 and its Current Ratio is at 7.38. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.

On August 30, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $9.

On August 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $6.H.C. Wainwright initiated its Buy rating on August 30, 2024, with a $6 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 06 ’24 when GOOD JENNIFER L sold 4,219 shares for $3.03 per share. The transaction valued at 12,784 led to the insider holds 213,313 shares of the business.

GOOD JENNIFER L sold 1,840 shares of TRVI for $5,587 on Sep 09 ’24. The President & CEO now owns 213,313 shares after completing the transaction at $3.04 per share. On Sep 05 ’24, another insider, GOOD JENNIFER L, who serves as the President & CEO of the company, sold 40,277 shares for $3.11 each. As a result, the insider received 125,310 and left with 213,313 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 191395584 and an Enterprise Value of 127015624.

Stock Price History:

The Beta on a monthly basis for TRVI is 0.97, which has changed by 1.09375 over the last 52 weeks, in comparison to a change of 0.27870452 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $4.00, while it has fallen to a 52-week low of $1.10. The 50-Day Moving Average of the stock is -15.96%, while the 200-Day Moving Average is calculated to be -15.09%.

Shares Statistics:

It appears that TRVI traded 515.81K shares on average per day over the past three months and 427180 shares per day over the past ten days. A total of 75.45M shares are outstanding, with a floating share count of 43.76M. Insiders hold about 43.08% of the company’s shares, while institutions hold 41.08% stake in the company. Shares short for TRVI as of 1732838400 were 1413263 with a Short Ratio of 2.74, compared to 1730332800 on 1716395. Therefore, it implies a Short% of Shares Outstanding of 1413263 and a Short% of Float of 2.8499998.

Earnings Estimates

Investors are eagerly awaiting the insights provided by 7.0 analysts currently analyzing and rating the stock of Trevi Therapeutics Inc (TRVI).The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.11 and low estimates of -$0.14.

Analysts are recommending an EPS of between -$0.45 and -$0.52 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is -$0.48, with 7.0 analysts recommending between -$0.38 and -$0.58.

Most Popular